Penelope Gray

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Journal article: LANCET INFECTIOUS DISEASES. 2025;:S1473-3099(25)00358-5
The challenges of immunobridging without established correlates of vaccine-induced protection.
Gray P
Article: JOURNAL OF INFECTIOUS DISEASES. 2025;231(4):e638-e649
Population-Based Age-Period-Cohort Analysis of Declining Human Papillomavirus Prevalence
Gray P; Wang J; Kleppe SN; Elfstrom KM; Dillner J
Article: INTERNATIONAL JOURNAL OF CANCER. 2024;155(9):1549-1557
Low methylation marker levels among human papillomavirus-vaccinated women with cervical high-grade squamous intraepithelial lesions
Louvanto K; Verhoef L; Pimenoff V; Eriksson T; Leppala S; Lagheden C; Gray P; Scibior-Bentkowska D; Sumiec E; Nieminen P; Dillner J; Berkhof J; Meijer CJLM; Lehtinen M; Nedjai B; Heideman DAM
Article: FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY. 2024;14:1437704
Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ-population-based follow-up of two cluster-randomized trials
Lehtinen M; Gray P; Luostarinen T; Eriksson T; Apter D; Bly A; Harjula K; Heikkila K; Hokkanen M; Kuortti M; Nieminen P; Nummela M; Paavonen J; Palmroth J; Petaja T; Pimenoff VN; Pukkala E; Dillner J
Article: NPJ VACCINES. 2024;9(1):146
Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study
Gray P; Mariz FC; Eklund C; Eriksson T; Faust H; Kann H; Mueller M; Paavonen J; Pimenoff VN; Sehr P; Surcel H-M; Dillner J; Waterboer T; Lehtinen M
Article: PLOS ONE. 2024;19(7):e0305285
Seroepidemiological assessment of the spread of SARS-CoV-2 among 25 and 28 year-old adult women in Finland between March 2020-June 2022
Gray P; Eriksson T; Skoglund L; Lagheden C; Hellstrom C; Pin E; Suomenrinne-Nordvik A; Pimenoff VN; Nilsson P; Dillner J; Lehtinen M
Article: INTERNATIONAL JOURNAL OF CANCER. 2024;154(9):1537-1548
Scientific approaches toward improving cervical cancer elimination strategies
Lehtinen M; Bruni L; Elfstrom M; Gray P; Logel M; Mariz FC; Baussano I; Vanska S; Franco EL; Dillner J
Article: ELIFE. 2023;12:e80905
Cervical cancer screening improvements with self-sampling during the COVID-19 pandemic
Elfstrom M; Gray PG; Dillner J
Article: CELL HOST & MICROBE. 2023;31(11):1921-1929.e3
Ecological diversity profiles of non-vaccine-targeted HPVs after gender-based community vaccination efforts
Pimenoff VN; Gray P; Louvanto K; Eriksson T; Lagheden C; Soderlund-Strand A; Dillner J; Lehtinen M
Article: JOURNAL OF INFECTIOUS DISEASES. 2022;226(7):1195-1199
Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses
Arroyo Muhr LS; Eklund C; Lagheden C; Eriksson T; Pimenoff VN; Gray P; Lehtinen M; Dillner J
Article: BMJ OPEN. 2021;11(12):e050669
Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Bly A; Gray P; Harjula K; Heikkila K; Hokkanen M; Karttunen H; Kuortti M; Nieminen P; Nummela M; Paavonen J; Palmroth J; Petaja T; Pukkala E; Soderlund-Strand A; Veivo U; Dillner J
Article: LANCET INFECTIOUS DISEASES. 2021;21(10):1458-1468
Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials
Mariz FC; Gray P; Render N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel H-M; Waterboer T; Mueller M; Pawlita M; Lehtinen M
Article: PLOS MEDICINE. 2021;18(6):e1003588
Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial
Gray P; Kann H; Pimenoff VN; Eriksson T; Luostarinen T; Vanska S; Surcel H-M; Faust H; Dillner J; Lehtinen M
Article: INTERNATIONAL JOURNAL OF CANCER. 2020;147(12):3511-3522
Long-term follow-up of human papillomavirus type replacement among young pregnant Finnish females before and after a community-randomisedHPVvaccination trial with moderate coverage
Gray P; Kann H; Pimenoff VN; Adhikari I; Eriksson T; Surcel H-M; Vanska S; Dillner J; Faust H; Lehtinen M
Article: INTERNATIONAL JOURNAL OF CANCER. 2020;147(2):440-447
Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women
Louvanto K; Eriksson T; Gray P; Apter D; Baussano I; Bly A; Harjula K; Heikkila K; Hokkanen M; Huhtinen L; Ikonen M; Karttunen H; Nummela M; Soderlund-Strand A; Veivo U; Dillner J; Elfstom M; Nieminen P; Lehtinen M
Article: INTERNATIONAL JOURNAL OF CANCER. 2019;145(3):785-796
Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV)
Gray P; Luostarinen T; Vanska S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Soderlund-Strand A; Dillner J; Lehtinen M
Article: INTERNATIONAL JOURNAL OF CANCER. 2018;142(12):2491-2500
Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II)
Gray P; Palmroth J; Luostarinen T; Apter D; Dubin G; Garnett G; Eriksson T; Natunen K; Merikukka M; Pimenoff V; Soderlund-Strand A; Vanska S; Paavonen J; Pukkala E; Dillner J; Lehtinen M

Alla övriga publikationer

Review: INTERNATIONAL JOURNAL OF CANCER. 2025;156(10):1848-1857
Scientific approaches to defining HPV vaccine-induced protective immunity
Lehtinen M; van Damme P; Beddows S; Pinto LA; Mariz F; Gray P; Dillner J
Letter: INTERNATIONAL JOURNAL OF CANCER. 2023;153(6):1313-1315
HPV16 E6-antibody associated risk of oropharyngeal cancer increases by calendar-time: A nested case-control study
Lehtinen M; Butt J; Gray P; Brenner N; Eriksson T; Lehtinen T; Luostarinen T; Schroeder L; Surcel H-M; Makitie A; Pimenoff VN; Waterboer T
Editorial comment: EXPERT REVIEW OF VACCINES. 2022;21(6):735-738
In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers
Lehtinen M; Gray P; Louvanto K; Vanska S
Preprint: SSRN ELECTRONIC JOURNAL. 2019
Population-Based Human Papillomavirus Serosurvey Reveals HPV16/18 Herd Effect But No Clear Type-Replacement in Unvaccinated Females 6 Years Post Gender-Neutral Vaccination in a Cluster Randomised Trial
Gray P; Artemchuk H; Pimenoff VN; Eriksson T; Luostarinen T; Vänskä S; Surcel H-M; Faust H; Dillner J; Lehtinen M

Anställningar

Postdoktor, Klinisk vetenskap, intervention och teknik, Karolinska Institutet, 2025-2027
Anknuten till Forskning, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2024-2026
Postdoktorala Studier, Klinisk vetenskap, intervention och teknik, Karolinska Institutet, 2023-2025

Artiklar

Alla övriga publikationer

Anställningar

Nyheter från KI

Kalenderhändelser från KI